Skip to content
Head to head

Lakefront Biotherapeutics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: LKFT · VRTX

Updated 7 minutes ago

1-year performance, rebased to 100

LKFT +8.3%VRTX +18.7%
It’s close.
LKFTVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price33.31515.02
Change today-0.24%-1.08%
1-year return+10.2%+22.0%
Market cap$2.18B$130.58B
52-week range25.68 – 36.24412.27 – 568.67
Valuation
P/E (TTM)2.5133.14
P/E percentile, own 5-yr range61st99th
P/B0.626.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)5.3415.32
Net profit (TTM)$349.75M$3.88B
Revenue (TTM)$926.99M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)-89.4%+11.8%
Gross margin98.0%85.5%
Operating margin65.8%33.1%
Net margin85.9%30.7%
Free cash flow (TTM)$-201.51M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership97.1%96.8%
Insider activity (12mo)0 buy / 0 sell28 buy / 22 sell
Short interest (% of float)2.0%1.9%
Analyst consensus100% buy (2)95% buy / 5% hold (21)
Analyst price target$45 (+35%)$624 (+21%)
StockVane view
StockVane Quant RatingC (52)C (68)
Company
Employees4526,400
Founded19991989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.